Alk-Abello As B Shs New

Hello, everyone, and welcome to this presentation of ALK's Q1 results. Thank you all for joining us. Let's turn to slide number two with an introduction to the speakers and the agenda. My name is Peer Plotnikoff. I'm Head of Investor Relations, and with me are CEO Peter Helling and CFO Klaus Stiltsen, Sergio. Peter and Klaus will walk you through the highlights, markets, product trends, and financial. And after a strategic update where we'll focus on peanut allergy, our respiratory tablets, and the nephew rollout, we will turn to the full year outlook. As usual, we will end the call with a Q&A session. And to get started, I'll hand you over to Peter on slide three. Please go ahead, Peter.

Thank you, Peter. Thank you all for taking the time to listen to this call. ELK had a very solid start to the year with revenue and earnings constantly exceeding the upper end of the full year guidance range. EVA grew by 22% yielding a margin of 32% on the back of an 18% revenue growth to 1.8 billion DKK. For the first time ever, ELK's total tablet sales exceeded 1 billion DKK in a single quarter. The results were furthermore supported by an improved gross margin reflecting some seasonality in the sales mix with a relatively high proportion of European tablets which carry higher margins. As guided, we expect this to somewhat normalize over the year as partner-related revenue increases. On the strategic side, the pediatric tablets are now marketed in the majority of our key European and North American geographies. and they are increasingly contributing to the inflow of new patients. Anaphylaxis sales also performed well, especially supported by JAXT. It is still early days regarding the FE sales, but we continue to develop market access, and we have secured further regulatory approvals, starting with the 2 milligram approval in Canada, an important market going forward, and the 1 milligram version in the EU for younger children, also an important segment. Both we expect to have first launches in the second half of this year. On April 20th, we announced the long-awaited Phase 2 results for our peanut allergy tablet. The successful completion of the trial is very encouraging and a first proof of concept of our tablet technology in food allergies. Based on the strong start of the year, we have upgraded the full year outlook. All of this will be detailed further during the presentation, but first I'll hand it over to you, Klaus, for the regional trends on slide 4. Thanks, Peter.

Let's take a closer look at performance in the regions. In Europe, revenue was up 19%. Germany, Europe's largest AIT market, delivered a strong double-digit tablet growth, and tablet sales in France also grew by double digits, maintaining the positive trend of recent years. This is partly compensating for lower slip drops revenue in France. We also saw high double-digit growth in several Eastern European countries, and in the UK, where Kai Sachs and Etude Sachs were admitted to the NHS last year with general reimbursement. In the EU, sales of anaphylaxis and other products increased by 47%, with the anaphylaxis portfolio in isolation up 58%. The main driver was GEXT, benefiting from high replacement rates in the UK and earlier tender wins in Southern Europe. Europe netty revenue was still modest as we are building access in many markets, including the UK. We still expect to see increasing uptake over the course of the year. Revenue in North America increased by 16% in local currencies, driven by a double-digit growth in both the USA and Canada. This was fueled by a strong demand for tablets in Canada for all brands and age groups. In the USA, revenue benefited from the cost compensation arrangement with AIS Pharma related to the co-promotion of NIFI. In international markets, revenue grew by 17% in local currencies. The growth reflected the timing of product shipments to China and Japan. Skid shipments to China saw a substantial increase compared to Q1 2025, when these were on hold during the renewal of our import license. In Japan, we have been through a period of soft growth due to phasing of shipments, capacity constraints, and the new owner standstill during the completion of the takeover of Torii. But in-market tablet sales recorded by Shinobi grew by double digits, and we remain comfortable that our full-year tablet revenue growth from international markets will re-emerge with double digits, supported by Taurus' expansion of API manufacturing capacity. Let's continue on slide 5 for the product lines. As Peter mentioned, then we reached quite an impressive milestone in Q1. We are proud to have reached 1 billion DKK in tablet sales for a quarter for the very first time. In Europe, recent quarters have delivered approximately 20% growth in tablet sales, but Q1 saw 26% growth, mainly driven by higher volumes, linked to a continued strong inflow of new patients over the past year. Sales of all tablet brands grew by double digits, and the highest gross contribution came from Etrura Saks and Akai Saks, increasingly driven by the relatively new indications for children and adolescents. Tablet sales also grew by 26% in North America, while international markets by contrast saw a 17% decline following fewer product shipments to Japan, partly offset by the double-digit revenue growth in the minor tablet markets of Southeast Asia, the Middle East, and Australia. Skid and slip drop sales were up 15%, so 566 million Danish kroner. Skid shipments to China resumed after being paused last year, and growth in European skid sales was mainly driven by Venom products. Conversely, slid drop sales were down in France, as mentioned. Sales of anaphylaxis and other products increased by 31%, with very strong growth in anaphylaxis-related revenue driven by Dext autoinjector. Nafi also contributed to this growth. Global growth in anaphylaxis alone sales was 84%. Now let's turn to slide 6 for the financials. Revenue increased by 18% in local currencies to nearly 1.8 billion Danish kroner on double-digit growth across sales regions and product lines. A gross profit of more than 1 billion Danish kroner yield a gross margin of 69% and improvement of 2 percentage points driven by higher sales volumes, changes to the product mix and production efficiencies. ALK branded products with higher margins accounted for a fairly high proportion of sales in Q1. However, for the rest of the year, the share of partner related revenue with lower margins is expected to increase. Capacity costs increased by 23% in local currencies to 658 million Danish kroner after significant investments in current and future growth initiatives, including additional sales resources, as we mentioned during the Q4 earnings call. The operating profit improved by 22% in local currencies to 570 million Danish kroner, raising the EBIT margin to 32% from 31%. Progress was linked to higher sales and improved gross margin, while the capacity cost-to-revenue ratio increased slightly to 37%, in line with our forecast for 2026. The net profit increased to 437 million Danish kroner. Cash flow from operating activities was 761 million Danish kroner, mainly driven by higher earnings and changes in working capital. Free cash flow was positive at 671 million bench kroner. All in all, a very strong set of results impacted by operation leverage and some seasonality, supporting a high gross margin versus the full year guidance. So now let's turn to slide 7 for the peanut allergy results and then to the status of other strategic initiatives. Please go ahead, Peter.

Thanks, Klaus. Thanks. We are very encouraged by the positive results from our Phase 2 Alliance trial of the tablet for treatment of peanut allergy. This is an important milestone, and as I said in the beginning, the first proof of concept for ARK's tablet technology in food allergy. The trial demonstrated clear dose-dependent and statistically significant efficacy across multiple clinical endpoints. And it is the first time ever anybody has demonstrated a convincing treatment effect with AIT in food allergy after just six months of treatment. Obviously, we are also thrilled about efficacy being observed across all age groups from children to adults. Importantly, the treatment was safe and well tolerated with low discontinuation rates and no treatment-related anaphylaxis or serious adverse events. Based on these results, we will rapidly advance the peanut tablet interface through clinical development, which we expect to initiate in the late part of 26, pending regulatory feedback on the trial design. The FDA's fast-track designation for the program will hopefully support a constructive dialogue with the agency. Now, let me just add a quick overview of the unmet needs we are addressing. Peanut allergy is an immune defect where even tiny amounts of peanut protein can trigger traumatic and immediate reactions, including life-threatening anaphylaxis. It typically begins in early childhood and often continues into later life. It is one of the most severe food allergies and a leading cause of anaphylaxis. Today, more than 10 million people in Europe, the US, and Canada live with peanut allergy, and over 3 million of them are children and adolescents. Treatment options remain limited. For some of these patients, sublingual immunotherapy tablets may become a relevant option with the potential to improve quality of life for patients and their families. As part of our broader food allergy portfolio approach, We've also seen positive and encouraging progress on ALK-014. ALK-014 is a biologic candidate targeting the allergic immune response system. This project could potentially enter clinical development in 27 and may be applied to food allergy as well as other IgE-mediated allergic diseases. So in other words, an anti-IgE. Now, let's continue to slide 8 for a closer look at the execution of other areas of our allergy plus strategy. So firstly, let me just give you a brief update on our strategic initiatives in the respiratory area and anaphylaxis. Starting with respiratory allergy, the pediatric tablet rollout continues to perform well. By end of Q1, the Houseless Mite tablet was launched in 21 markets, including North America, and the Tree Pollen tablet in the 13 markets. Key performance indicators remain strong. More than 4,000 prescribers in our directly served markets have now prescribed at least one or two tablets to children. Around 20% of these doctors have not prescribed any ALK tablets before. which indicates that we are expanding our prescriber base in existing markets. With TAPTIS now launched in the majority of key markets, the focus shifts to increase penetration and sustain prescriber adaption. We also continue to progress our partnerships. In China, ACARISAX phase 3 patient recruitment has been completed, with the trial expected to finalize around the turn of the year. In Japan, the GRASAX phase 3 trial is progressing towards completion in early 27. So let me spend some time on NEFI. First, on regulatory progress. In Q1, the European Commission approved the 1 milligram version of Euronefi for children aged 4 years and older, weighing between 15 and 30 kilograms. We expect the first launches from the product in the second half of this year. This was a milestone, as your NEFI is the first and only needle-free adrenaline treatment in Europe, now available in two dose trends. In addition, the 2mg version was approved in Canada in April, with launches expected just after the summer. Beyond approvals, we are working intensively on market access, going through the grind, so to speak. In the UK, national approval and pricing were settled last year, But the UK is also a market where we need to make sure the product is accessible and reimbursed on a local level. So to actually reach patients, the product needs to be listed among the 42 local formal areas across the UK. We are working through this process systematically, and it is expected to continue through most of 26 and into 27. So while the UK represents a large opportunity, the revenue contribution will build gradually from the second half of the year and onwards. An important highlight in the UK in Q1 was as new legislation mandated all schools to have readily available adrenaline devices for emergency cases. This legislation mentions both adrenaline autoinjectors and nasal sprays such as NEFI. In Germany, Our first market, NEFI, is generating revenue, and a sound market share has been maintained. Although we are still in the early market shaping phase, working to change long-standing prescribing habits. If we look at the US, the co-promotion agreement with the US is progressing, but is also faced with market access hurdles that need to be overcome. More broadly, market access and launch preparation is ongoing in around 17 additional countries. So to sum up on NEFI, Q1 revenue was modest, as expected, but we do expect an increase in contribution from the second half of 26 and into 27, as more markets and regulations come online and are opening up new areas. Now, I'll hand it back to you, Klaus, and the full year outlook on slide 9. Thanks, Peter.

We upgraded the full-year revenue outlook with increased confidence based on the sustained momentum for tablet sales, particularly in Europe, and at the same time we have seen an improved risk picture. We now expect revenue to grow by 13-16% in local currencies, up from the previous outlook of 11-15% growth. The EBIT margin outlook is also upgraded and is now expected at around 26%. we are still allocating significant investments to initiatives to bolster long-term growth and profitability. These include commercial investments into tablets, including the children rollout. We are also investing into NEFI and expanding the commercial infrastructure in the UK, Canada and other markets. Furthermore, we are also advancing our investments into AI. I would also like to stress that the long-term financial ambitions are currently unchanged. Let me take you through the main assumptions. We expect volume-driven revenue growth across sales regions and product groups. The lower end of the 13% to 16% range reflects microeconomic uncertainties, including potential negative impact from price and rebate adjustments, even though this has been partially de-risked. It also includes lower growth in skid and slip-drop sales. The upper end assumes stable price and rebate conditions and potentially upsides for tablet and anaphylaxis sales. As usual, the timing of shipments to international markets may lead to quarterly fluctuations. Tablet sales are expected to grow by double digits. Skid and slid drops revenue is projected to grow by single digits, while sales of anaphylaxis and other products are expected to grow by low double digits, with an increasing contribution from NEFI in the second half year. The gross margin is now expected to be on par with last year, reflecting the strong tablet momentum in Europe. We still expect a relatively higher growth in partner-related revenue at lower margins in the remainder of the year, primarily from shipments to Japan and China, as well as Navy sales, which also hold lower margins. Capacity costs are projected to increase, but the capacity cost-to-revenue ratio is expected to be largely unchanged as ALK reinvests the benefits of increased scales into key strategic growth opportunities. So to sum up, we expect to continue our trajectory of double-digit organic revenue growth with an EBIT margin which is slightly above our long-term earnings ambitions. So once again, we are very satisfied with the results of Q1 and the current business momentum. With this, I hand it back to you, Pierre, and slide two.

Thank you, Klaus, and thank you, Peter. And this concludes our presentation, and we will now open up for the Q&A session. Operator, please go ahead.

Thank you. We will now begin the question and answer session. To ask a question, you may press star, then one on your touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, and then two. At this time, we'll pause momentarily to assemble our rosters. The first question will come from Thomas Bowers with SEP. Please go ahead.

Thomas Bowers Yes, thank you very much. Three questions from my table here. So, just firstly on peanuts, do you believe the high dose that you used in the phase two was optimal given the low incidence of X versus the influence observed from that trial dose? So is there a scope to push those things higher in the phase three to optimize the efficacy or do you think that you already at the current level are close to what you would say efficacy ceiling? And then the second question is just on remaining risks in regards to the pricing reforms or intrinsic discounts in Germany. So from my understanding, the current proposal is 3.5% discount starting January 27, but you are also still including some risks in 26, or maybe it's only the macro uncertainty. But is there any uncertainty to timelines there, and then also... That 3.5% could be seated at the one-year interim or what's sort of in the planning here. And the last question just on the LK14 question. So first time you sort of disclosed the target. So could we see this as a potential next generation Solaire? Is anything different with the O14 in terms of blocking IGE? And also, how should we compare this to, for example, OCRF from RAS with the three-month dosing? So anything that can differentiate LK14, given that you are a few years behind that? Thank you.

Thank you, Thomas. Let me start out just on peanuts. I'll have Klaus talk about the risks in Germany, and then I'll also comment on ERK14 in the end. So we have been looking obviously at the data and the dosing on the phase two. We believe it looks to be at the right range. Could one benefit from higher dose? I think it's a matter of looking at dosing and also dosing. and we feel we are quite in a good place for the current dosing. So we do not at this stage, and I'll just underline at this stage, expect to change dosing given the positive results. What is more important is obviously that we receive good results in only six months, so we may benefit from a longer timeline on the phase three trial. So I think that's the answer to that one. And then on the risk, Klaus.

Yes, should I just take that? Thanks so much for the question. Let me start by saying that we are only in the beginning of May, right? So there could be other pricing risk hitting us during the year that we are not that much aware about at that point in time or at this point in time. But let me focus on the German one that you asked too. It is correct that actually last week then in the German Parliament they came forward with a suggestion to actually not have any German rebate here for 26 years. But they let it start from 1st of January of 27 with 3.5% on top of the 7% that is already there, so 10.5%. What it also suggested was that that was only going to be for the first half of 27 and then for the second half of 27 they didn't really know what to do but this should more be a a percentage that could actually follow something and that's something we don't know what it is. It could, for example, be the price increases or the medical prices in the market. What we are saying right now is that this is still highly uncertain, it's not implemented yet, and we do not really know what will happen. We have heard that there are still voices in the German parliament that believes that the pharma industry are getting off the hook too easy, if I can say it like that, here for 26, and that there should be something implemented over the second half of the year. We do not know if that is coming and that's why we are flagging it as a risk and as a potential downside. But you are right that right now it's more suggesting coming from 1st of January and then that's it. Whether or not it's a one-year impact, we actually do not know yet. It could be a two or three year. They are not very specific about that.

So I will leave you with that. Thanks Klaus. Just on ALK014, you asked whether this is a next generation Solera wrapped. I think it's an anti-IgE. Obviously we are looking at what's in the market and we're also looking at the data we have available and done in animals. Do remember this is preclinical. And we think it's encouraging, and we also think, obviously, it's encouraging enough that we are considering whether this should move into a phase one. This would be a natural build-on in terms of our food allergy portfolio. So I promise you, Thomas, we'll be able to disclose more as we progress, but we thought it was important to flag because we know it's a question that has been popping up. So we do have an interesting molecule. It works slightly different than what you see otherwise, but we think it's highly relevant also going forward, not only for food allergy, potentially for more indications given it's a broad anti-IgE. So I think I'll leave it at that, and then I'll promise you that we'll come back later in the year when we have a little more clarity in terms of where we stand and when we'll move it forward. If we move it forward, the ambition will be to start it up around year end and into the new year, and that would obviously be a phase one, so focusing in on the safety aspects of the molecule in humans. Good. All right, I hope that answers. That's great.

Thank you. Thank you. The next question will come from Benjamin Jackson with Jeffrey. Please go ahead.

Brilliant. Thank you for the question. Two topics for me. The first, if I can just follow up on Tina, hearing what you're saying about the dosing, and you also mentioned obviously this response is what we're seeing at six months, but perhaps you could comment on what else you think could be done going into the Phase 3 that could perhaps further enhance the results. that you're seeing, such as a longer maintenance or something different in the up titration phase. And then off the back of that, when you're looking at the data that you have at hand now, can you see the response rates improve with time, and therefore there would be reason to dose out for a 12-month period that seems to be more standard when you look at competitors in this food allergy space? Yes. And then the second topic, I just want to touch on M&A a little bit and potential BD. Generating a lot of cash now, low leverage. So is this becoming a bigger part of your agenda or portfolio decisions going forward? And then off the back of that, what should investors expect in terms of the sizing and phenotype of any potential deals that happen? That would be great. Thank you.

Thanks, Ben. Peter speaking. I think I ended up with answering both. So, no, I think on the peanut, obviously, the breadth and the depth of a phase three is bigger with the prescriber basis and the population or the cohorts we're putting in. That alone provides us opportunity to optimize further. We obviously learned a number of things in terms of how we can ensure that this is running even better, and that will hopefully help also improve the results, but that remains to be seen. When we look at the maintenance, then we will be looking at something which is likely closer to what you've seen from others conducting these trials, and we do that because we believe that we'll see even better results than we did in the first part. In terms of the dosing of schemes, et cetera, that's obviously a dialogue also with the FDA in terms of what are their expectations, what are ours. refrain from answering that but we do obviously think about this also from a prescriber standpoint and from a patient standpoint so it becomes more efficacious and also easier for all parties involved in terms of running and conducting the trial but obviously also afterwards where we hope to launch the product. So I think we will do obviously what we can to optimize going forward. The dialogue with the FDA will start hopefully shortly, and then as soon as we can, we'll also talk more broadly around how we're conducting and setting up the study design. So on the M&A and BDL, I think that the short answer is we'll announce when and if we do more. That being said, yes, we are aware that we're generating cash We said it all along, this is part of our strategy. We are looking on an ongoing basis, but it's a matter of both price and also relevance for us as a company. I think the good news is we still have plenty of things to do with our current business areas to invest in. So I'll remind you of what we did at the Capital Markets Day. Organic growth remains a top priority for the company. And then inorganic growth in relevant areas and where we can help expand our portfolio. That can either be in licensing. It could also be M&A. But if something is out there that can help us both from a portfolio standpoint but also from a geographical standpoint, that could be relevant and that we will continue to monitor. So I promise you, as soon as we have something, we will share it soon and if, just to be clear. So I cannot get any further into that, but I hope that at least gave you some helping insights.

Yeah, easily. Thank you so much. The next question will come from Jasper and Justin with B&B. Please go ahead.

Thanks. I have a few questions. I'm just wondering if you could elaborate a bit concerning the calls related to potentially some How long do you think you'll be able to press this before having to partner up? I guess this is in the context of what we've seen in terms of some of the big pharma companies looking at assets in this space, for example, just a few weeks ago. On Treenut, I don't see any mention of you guys progressing that at this point in time. My understanding was kind of that you were going to progress that on the back of a positive base to data core for Treenut. And then lastly, a question on NetEase, if we could get an update on the market share you have achieved so far. I think it was 18% at the end of I appreciate Germany is still not the largest market to have the licensing agreement for. I'm just trying to understand why this is still not showing up in the numbers more materially.

Sure. Thanks, Jesper. Peter again. So just on LK014, do remember this is preclinical. We need to move it forward. So we think about partnerships, et cetera. First and foremost, the key is to ensure we have relevant data that we can take a hard look at and obviously potentially others. I think that would be natural with a Phase 1. ELK have no intentions of becoming a biologic company as a standalone. But that being said, when we have interesting assets in the pipeline and we generate a lot of new knowledge, obviously we also feel it's important for us to take a look at that and progress it. When we look at trial designs, et cetera, it's not that different from how you would run AIT clinical studies, so we are fairly comfortable around conducting that. But the data will tell us whether we believe we need partners or if we can do this on our own. In terms of Treenut, Treenut is still relevant for the company, but obviously we are taking a look at this from a portfolio standpoint and also with the LK014 and obviously with the PNUT trial going into Phase 3, we still need to get some feedback from the FDA in terms of what are the expectations for PNUT, and we can use that to inform us in terms of how should we be looking at something like Treenut trials. So bear with us a bit. It's not on purpose we're leaving it out. It's basic simply because we need to get through the FDA interactions and kind of get the sign on the phase three. That will also inform us on how we should think about peanut potentially, sorry, tree nut potentially. Then your question on NEFI. Pretty much when we look at Germany, the way we look at it, we will see fluctuations on a monthly basis. We think we've hit an initial plateau. We haven't done a lot to progress markets here. But what we do like and what we see in the numbers is that we are getting increasing amount of patients on the product overall. And in combination with JEXT, we actually think that our portfolio strategy is working quite well. As we said early on, both Klaus and I talked about it, then NAEFI is expected to go through all the regulatory hurdles, the one milligram approvals, but also individually in the local markets. And hence we also believe it becomes more meaningful to talk about the uptake when we get into the later part of 26, most likely into 27, depending on the pace. But all in all, to conclude, I think we are at a pretty good place initially, but still we are talking low volumes overall, and that's also why we are a little cautious. Market share remains at a good level, and we are seeing a decent patient uptake, so all in all, positive.

Thank you. The next question will come from Susila Hernandez with Ben Lanshaw Kempner. Please go ahead.

Yes, thank you for taking my questions. Also on the PNIT program, is your base case exploring the devlet in the 4 to 65-year-olds, or is it possible to also go lower? And could you share more color on discontinuation rates in the phase 2 study? Is there a difference between the age groups? Thank you.

Yeah, so this is Peter. So we are looking at going over, so basically all the way down to one year to answer a question. Obviously, again, depends on the interactions with FDA, but ideally we would. So that would be an expansion of the program. Then you have the second part, and you just – could you repeat, Sheila, on the second part of the question?

Yes, so – the discontinuation rates in the Phase 2 study. Is there a difference between the age groups? Could you provide more color?

I will have to... Do you know, Per, if... I actually don't know how much... We have no further details of this at this stage.

This will be presented at a medical... But please remember that the discontinuation levels in general were very low. So we're only talking about a few patients on active treatments and also... a few on placebo, so it was quite low. So it's very difficult to talk meaningfully about discontinuation levels in different age groups. The study is simply too small to do that on a meaningful basis.

Okay, that's clear. Thank you.

Again, if you have a question, please press star and then 1. The next question will come from Peter Hughgriff-Ankerson with Nordea. Please go ahead.

Thank you for taking my questions. Just a few, if I may, maybe for you, Klaus, around the margins. You're guiding around 25% monitoring longer term, and now we start seeing 26%, and maybe even moving upwards. Should we think about 2026 and beyond in terms of the market development? Is it just a blip, and then you'll come back, or how should we think about that? So that's the first thing. And then secondly, just I was intrigued around the M&A discussion, so maybe just a little bit more context in terms of are you looking at more transformational deals or just smaller bulldogs or anything in between? If you could share any of the light on that, and then I will spare you for more peanut questions, you know.

Thanks, Peter.

Klaus, thanks, Peter. Good to hear from you. You're right that now we have increased to the 26%. And, of course, we are not kind of guiding on next year's EBIT margin already now. But I think what is interesting to... take into consideration is that if you look into next year, then we are especially starting the peanut, which is also how can a peanut matter, peanut phase three trials, so 27 and 28. Here we are going to invest significantly into the peanut trials, and you will see an increase there. Depending on, of course, also now we talk about LK014, where that will go with the preclinical and so on, then you could also see increased investments into that. So overall, the R&D investments will increase. On top of that, then there's no doubt we will continue our commercial investments. Those with the children's launches continue to invest into that, but especially next year also the nephew launches across the world. So that will be our second parameter also. So there's no doubt that next year we will aim for the 25% EBIT margin as we have in our long-term financial targets. And that's, of course, a deliberate decision we are making to make sure that we invest for both top-line and bottom-line growth in the years to come.

I hope that puts some flavor to it. And Peter, as much as I love to talk details around M&A and BDNL, it's difficult to add a lot more flavor. I do think what's important to say, though, and the way you should think about it, I think we have a company, we still have a number of growth avenues. What we said all along is when we look across our segments, we think it's relevant to invest in assets that can contribute to to a portfolio strategy, enabling us to get a strong position globally, including in North America, US, Europe, but also potentially Asia, but ideally will expand. What we did with the NAFI deal, was a license deal that gave us a global asset excluded the US though and a few other countries but it actually made a good relevance or relevant contribution to our portfolio and that's how we think about it and we obviously also think about it in the food allergy space and if something came up that was relevant in respiratory, we would also be looking at that. So we are obviously looking at options. You're also seeing the price points out there in terms of assets, so it needs to be meaningful for ALK as well. So I cannot get more closer than that, but it's obviously on the agenda.

Can I ask the other way around then? You can try. Yeah, exactly. I know. I know. But just in terms of the cash pile then, because you can say at some point in time, then you will be sitting at, if things go according to plan, then you'll be sitting at a substantial cash pile. So how should we think about that? I mean, at what point in time is it that, is it when you start a huge buyback or is it when you increase the dividend? Or how should we think about that in terms of the cash that you'll be piling the coming years if you live up to your expectations?

It's easier for me to talk about how to spend the cash, and Klaus likes to talk about how to keep it. So, Klaus, you want to comment?

Thanks, Peter. I think there's no doubt that we have said all along that we like to have a disciplined capital allocation. So it basically means that if you're looking at our capital structure and how we are looking at this, Peter said it before, we would like to invest into our organic growth, and there's no doubt that we will spend as much as we can related to that cash into the commercial opportunities, into the R&D opportunities, and so on. On top of that, we also are investing into different areas like building our manufacturing capabilities, capacities where we also right now, for example, can produce up to these 500 million tablets. And we would like to increase to 800 million, also billion tablets also. So that we are also going to invest into in the years to come. And then it's correct, we have also said at the Capital Markets Day that we are not a bank. So when we have invested sufficiently enough into, you know, top line, organic, into the different facilities, into the BD and M&A that Peter is talking to that it's difficult to put a number on right now, then if there's anything left, then we would like to return it back to the shareholders. That was what we did this year for the first time where we now set up a dividend, 30% net profit. But of course, there are other ways of doing that, and you said yourself, either increase the dividends or looking into share buyback. So that could also be an opportunity, but it's too early to talk about it right now. But we will not pile cash and we will not be a bank. So when we have invested into the future, as we believe is the right thing to do, and if we have concluded there are no BDM&A activities, then we will look into increase the shareholder return. So that's the plan. Much appreciated. Thank you so much.

Thank you. Thank you so much. This will conclude our question and answer session. I would like to turn the conference back over to management for any closing remarks.

Thank you very much. Thank you all for the good questions. And before we end the call, let me just highlight a few upcoming events on slide 11, and we certainly hope to see you at one of these events. In any case, you are most welcome to get in touch if you have additional questions or comments. And with this, we will end today's session. Goodbye and have a nice day.